Vaccination for pandemic influenza and severe acute respiratory syndrome: Common issues and concerns

Clinical Infectious Diseases

Volumn 36, Issue 12, 2003, Pages 1562-1563

  Fedson, David S ^a  

^a NONE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; LIVE VACCINE; SEVERE ACUTE RESPIRATORY SYNDROME VACCINE; UNCLASSIFIED DRUG; VIRUS VACCINE;

CORONAVIRUS; COST BENEFIT ANALYSIS; DEVELOPING COUNTRY; DRUG EFFICACY; DRUG MANUFACTURE; DRUG RESEARCH; DRUG SAFETY; HEALTH CARE PLANNING; HUMAN; INFLUENZA; INFLUENZA VACCINATION; NOTE; PRIORITY JOURNAL; SARS CORONAVIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; VACCINE PRODUCTION; VIRUS PNEUMONIA; VIRUS STRAIN; WORLD HEALTH ORGANIZATION; VACCINATION;

HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; SEVERE ACUTE RESPIRATORY SYNDROME; VACCINATION; VIRAL VACCINES; WORLD HEALTH ORGANIZATION;

EID: 0037534140     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/376761     Document Type: Note

References (7)

1. Gerberding JL. Faster... but fast enough? Responding to the epidemic of severe acute respiratory syndrome. N Engl J Med 2003; 2030-1.
2. A vaccine against SARS will not be enough. New Scientist 2003; 178:5.
3. Milstien J, Lambert S. Emergency response vaccines - a challenge to the public sector and the vaccine industry. Vaccine 2002; 21:146-64
4. Milstien J, Glass S, Batson A, Greco M, Berger J. Divergence of vaccine product lines in industrialized and developing countries. Available at: http://www.who.int/vaccines-access/supply. Accessed 6 May 2003.
5. The Developing Country Vaccine Manufacturers Network (DCVMN). 28 April 2003. Available at: http://www, who.int/vaccines-access/supply/dcvmn_network_mission_final.htm. Accessed 6 May 2003.
6. Fedson DS. Pandemic influenza and the global vaccine supply. Clin Infect Dis 2003;35:1552-61 (in this issue).
7. The cost of SARS. New York Times. 1 May 2003.